EMEA committee rejects Novartis' Zelnorm
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has dealt Novartis a setback on Zelnorm for irritable bowel syndrome, deciding not to recommend the drug. Novartis, which saw its shares slip in the news, immediately announced that it would appeal the negative decision. "Although we are disappointed with the CHMP opinion, we are confident in the clinical profile and benefits of Zelnorm," Novartis' James Shannon said. Zelnorm is already on sale in the US and other countries.
- read this release for more information
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
